Orforglipron, sold under the brand name Foundayo, is a once-daily, oral small-molecule GLP-1 receptor agonist developed for chronic weight management and type 2 diabetes.
Unlike peptide-based injectables or restricted oral options, it requires no food or water timing rules.
Acts as a non-peptide, small-molecule GLP-1 receptor agonist.
Binds directly within the transmembrane domain of the GLP-1 receptor.
Slows digestion and targets appetite centers in the brain to reduce hunger.
Absorbs efficiently in the digestive tract without needing special enhancement tools.
Dosage and Administration
Taken as a once-daily oral tablet swallowed whole.
Standard starting dose is 0.8 mg once daily.
Gradually increased in stepwise increments (2.5 mg, 5.5 mg, 9 mg, up to 14.5 mg or 17.2 mg max) after at least 30 days per level.
Can be taken with or without food at any time of day.
Phase 3 trials show average body weight reductions of about 11% to over 12% at maximum doses over 72 weeks in adults without diabetes.
Lowers blood sugar levels and A1C effectively in adults with poorly controlled type 2 diabetes.
Administered alongside a reduced-calorie meal plan and increased physical activity.